BusinessHemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in EuropeBy Nasdaq OMXJan 26, 2017, 3:51 PM UTC
BusinessHemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer PatientsBy Nasdaq OMXJan 11, 2017, 1:31 PM UTC
BusinessHemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer PatientsBy Nasdaq OMXJan 11, 2017, 1:31 PM UTC
BusinessHemispherx Biopharma to Present at the 9th Annual LD Micro Main EventBy Nasdaq OMXNov 21, 2016, 1:30 PM UTC
BusinessHemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended September 30, 2016By Nasdaq OMXNov 14, 2016, 9:36 PM UTC
BusinessHemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15, 2016By Nasdaq OMXNov 10, 2016, 1:31 PM UTC
BusinessHemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15, 2016By Nasdaq OMXNov 10, 2016, 1:31 PM UTC
BusinessHemispherx Biopharma Featured in Corporate America News Magazine Special Report “Capturing the Power of Immune Response to Treat Disease: Biotech Bounce Back”By Nasdaq OMXNov 8, 2016, 1:30 PM UTC
